It’s certainly worth considering that since patients taking the 400mg dose only represent a very small percentage of the “blinded average response rate”, that group could have stellar efficacy and it would be nearly imperceptible in the still blinded results.
Even double or triple the previous response rate from only ~14% of patients in the trial would not make the overall numbers look that good until unblinding imho.